Antiretroviral Therapy, Highly Active
HIV Infections
Anti-HIV Agents
CD4 Lymphocyte Count
Viral Load
HIV-1
Acquired Immunodeficiency Syndrome
HIV
AIDS-Related Opportunistic Infections
Reverse Transcriptase Inhibitors
Drug Resistance, Viral
HIV Protease Inhibitors
Stavudine
Zidovudine
South Africa
Nevirapine
Medication Adherence
HIV-Associated Lipodystrophy Syndrome
Infectious Disease Transmission, Vertical
Cohort Studies
Drug Therapy, Combination
HIV Seropositivity
Immune Reconstitution Inflammatory Syndrome
Ritonavir
CD4-Positive T-Lymphocytes
Lopinavir
Lamivudine
Treatment Outcome
Organophosphonates
Treatment Failure
Pregnancy Complications, Infectious
Indinavir
AIDS Dementia Complex
Botswana
Lymphoma, AIDS-Related
Drug Resistance, Multiple, Viral
Lost to Follow-Up
Cytomegalovirus Retinitis
Didanosine
Nelfinavir
Coinfection
Malawi
Drug Administration Schedule
Prospective Studies
Directly Observed Therapy
Drug Monitoring
HIV Reverse Transcriptase
Retrospective Studies
Dideoxynucleosides
Risk Factors
Lipodystrophy
Cote d'Ivoire
Africa, Southern
Zambia
HIV Wasting Syndrome
Cross-Sectional Studies
Disease Progression
Follow-Up Studies
Tuberculosis
HIV Protease
Antitubercular Agents
Virus Replication
Prevalence
CD4-CD8 Ratio
AIDS-Associated Nephropathy
Plasma
Incidence
CD8-Positive T-Lymphocytes
Sarcoma, Kaposi
Developing Countries
HIV Long-Term Survivors
Longitudinal Studies
Saquinavir
Antiviral Agents
Zimbabwe
Pregnancy
Virus Latency
HIV Seronegativity
Acidosis, Lactic
Cameroon
Treatment Refusal
Thailand
Withholding Treatment
Haiti
Kenya
Hepatitis C
Multivariate Analysis
Proportional Hazards Models
Genotype
pol Gene Products, Human Immunodeficiency Virus
British Columbia
Toxoplasmosis, Cerebral
Survival Analysis
Drug Interactions
Meningitis, Cryptococcal
Health Services Accessibility
Rwanda
Pneumonia, Pneumocystis
Pyrrolidinones
Protease Inhibitors
Leukoencephalopathy, Progressive Multifocal
Mozambique
Logistic Models
Mutation
Trimethoprim-Sulfamethoxazole Combination
Proviruses
Leukocytes, Mononuclear
Tanzania
Health Resources
Virus Shedding
Genes, pol
Biological Markers
Simian Acquired Immunodeficiency Syndrome
Kaplan-Meier Estimate
Pilot Projects
Lymphocyte Activation
Dyslipidemias
Ambulatory Care Facilities
Molecular Sequence Data
Receptors, CCR5
Mycobacterium avium-intracellulare Infection
Socioeconomic Factors
Drugs, Generic
World Health Organization
Case-Control Studies
Ethiopia
Drug Costs
Cost-Benefit Analysis
HIV Integrase Inhibitors
Drug Combinations
Life Expectancy
HIV-2
HIV Fusion Inhibitors
Regression Analysis
Sequence Analysis, DNA
HIV Core Protein p24
Drug-Induced Liver Injury
Drug Users
AIDS Vaccines
T-Lymphocyte Subsets
Age Factors
Epidemics
Simian immunodeficiency virus
Clinical Trials as Topic
Epidemiologic Methods
Statistics, Nonparametric
Candidiasis, Oral
Nigeria
Mutation, Missense
Risk-Taking
Models, Statistical
Flow Cytometry
Lymphoma, Non-Hodgkin
France
Delivery of Health Care
Togo
Social Stigma
Sex Factors
Patient Dropouts
Gene Products, pol
Neopterin
Antigens, CD38
Questionnaires
Polymerase Chain Reaction
Hepatitis B
Asia
T-Lymphocytes
Influenza in three patients with human immunodeficiency virus infection. (1/4193)
Three Japanese outpatients with human immunodeficiency virus (HIV) infection on anti-retroviral therapy showed evidence of influenza in January 1999. CD4+ T cell counts of these patients prior to the diagnosis of influenza were 72, 248, and 152/mm3, and HIV RNA levels were 19,953, 1,259, and 1,585 copies/ml, respectively. Fever continued 4 to 5 days with no severe complications. One patient showed post-influenzal bronchitis which was effectively treated by antibiotics. None of these patients showed increased serum HIV RNA levels during and after influenza, however, in one patient, a transient reduction of CD4+ and CD8+ cells was seen during the active phase of influenza. Although symptoms of influenza in HIV carriers are generally mild and similar to those in healthy adults, careful follow-up is needed as symptoms of influenza in some HIV-infected patients can be prolonged and serious. (+info)The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. (2/4193)
A multicenter analysis of 57 consecutive human immunodeficiency virus-positive patients with progressive multifocal leukoencephalopathy (PML) was performed, to identify correlates of longer survival. JC virus (JCV) DNA was quantified in the cerebrospinal fluid (CSF) by polymerase chain reaction. Two months after therapy, 4% of the patients without highly active antiretroviral therapy (HAART) and 26% with HAART showed neurologic improvement or stability (P=.03), and 8% and 57%, respectively, reached undetectable JCV DNA levels in the CSF (P=.04). One-year probability of survival was.04 without HAART and.46 with HAART. HAART and lack of neurologic progression 2 months after diagnosis were independently associated with longer survival. Among HAART-treated patients, a baseline JCV DNA <4.7 log, and reaching undetectable levels after therapy predicted longer survival. Survival of AIDS-related PML is improved by HAART when JCV replication is controlled. (+info)Prophylaxis for opportunistic infections in an era of effective antiretroviral therapy. (3/4193)
Potent antiretroviral treatment is associated with dramatic improvements in immune function in many human immunodeficiency virus-infected patients. This has led to new US Public Health Service/Infectious Diseases Society of America guidelines that suggest that in certain circumstances (primary prophylaxis for Pneumocystis carinii pneumonia and disseminated Mycobacterium avium complex infection, and secondary prophylaxis for cytomegalovirus retinitis), antimicrobial prophylaxis can be discontinued for patients whose CD4 T-cell counts rise above threshold levels for at least 3-6 months. The new guidelines are probably too conservative, and effective antiretroviral treatment almost certainly provides protection against all major opportunistic pathogens. Therefore, in the future, specific prophylaxis will be needed only for those patients who do not benefit from or fail to adhere to the current more effective treatment of human immunodeficiency virus infection. (+info)The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the Women's interagency HIV study. (4/4193)
The relationship between the pattern of virus load response to highly active antiretroviral therapy (HAART) and CD4 lymphocyte response was assessed in a cohort of 249 human immunodeficiency virus (HIV) type 1-infected women at 3 times: 1 before and 2 after initiation of therapy, with follow-up of 6-12 months. Patients with a durable response to HAART (i.e., >1 log decrease in HIV-1 RNA sustained for the study periods) had a continuous and significant increase in CD4 cell counts over time, whereas those with no response (<0.5 log decrease in HIV-1 RNA) had a slight decline. Patients with a mixed response (initial decrease >1 log, followed by a subsequent decrease <0.5 log) had an increase in CD4 cell count, followed by a plateau. The trend in CD4 cell count differed significantly by response to HAART, with those patients who experienced a durable response having significantly higher CD4 cell counts than others. (+info)Evaluation of the abbott LCx HIV-1 RNA quantitative, a new assay for quantitative determination of human immunodeficiency virus type 1 RNA. (5/4193)
A new quantitative reverse transcription (RT)-PCR assay for human immunodeficiency virus type 1 (HIV-1) RNA (Abbott LCx HIV RNA Quantitative assay) has been compared with the Organon NucliSens assay on 521 retrospective samples obtained from HIV-1-positive patients monitored during highly active antiretroviral therapy, 79 of whom were assayed also by the Chiron Quantiplex 3.0 system and on characterized panels. The LCx system showed a moderate correlation (r = 0.795) and gave higher results than the NucliSens system on 245 of 327 concordant positive samples, with similar sensitivity. Correlation with Quantiplex system results was higher (r = 0.943). LCx reproducibility was very good; the procedure was simple, well controlled, and rapid (up to 48 results in 7 h). The HIV RNA quantitative assay on the LCx system is suitable for routine use. (+info)Granulomatous amebic encephalitis in a patient with AIDS: isolation of acanthamoeba sp. Group II from brain tissue and successful treatment with sulfadiazine and fluconazole. (6/4193)
A patient with AIDS, treated with highly active antiretroviral therapy and trimethoprim-sulfamethoxazole, presented with confusion, a hemifield defect, and a mass lesion in the right occipital lobe. A brain biopsy confirmed granulomatous amebic encephalitis (GAE) due to Acanthamoeba castellanii. The patient was treated with fluconazole and sulfadiazine, and the lesion was surgically excised. This is the first case of AIDS-associated GAE responding favorably to therapy. The existence of a solitary brain lesion, absence of other sites of infection, and intense cellular response in spite of a very low CD4 count conditioned the favorable outcome. We review and discuss the diagnostic microbiologic options for the laboratory diagnosis of infections due to free-living amebae. (+info)Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. (7/4193)
Despite prolonged treatment with highly active antiretroviral therapy (HAART), infectious HIV-1 continues to replicate and to reside latently in resting memory CD4(+) T lymphocytes, creating a major obstacle to HIV-1 eradication. It is therefore not surprising to observe a prompt viral rebound after discontinuation of HAART. The nature of the rebounding virus, however, remains undefined. We now report on the genetic characterization of rebounding viruses in eight patients in whom plasma viremia was undetectable throughout about 3 years of HAART. Taking advantage of the extensive length polymorphism in HIV-1 env, we found that in five patients who did not show HIV-1 replication during treatment, the rebound virus was identical to those isolated from the latent reservoir. In three other patients, two of whom had been free of plasma viremia but had showed some residual viral replication, the rebound virus was genetically different from the latent reservoir virus, corresponding instead to minor viral variants detected during the course of treatment in lymphoid tissues. We conclude that in cases with apparent complete HIV-1 suppression by HAART, viral rebound after cessation of therapy could have originated from the activation of virus from the latent reservoir. In patients with incomplete suppression by chemotherapy, however, the viral rebound is likely triggered by ongoing, low-level replication of HIV-1, perhaps occurring in lymphoid tissues. (+info)A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDS. (8/4193)
Preliminary preclinical and clinical data suggest that granulocyte-macrophage colony-stimulating factor (GM-CSF) may decrease viral replication. Therefore, 105 individuals with AIDS who were receiving nucleoside analogue therapy were enrolled in a placebo-controlled, double-blind study and were randomized to receive either 125 microgram/m(2) of yeast-derived, GM-CSF (sargramostim) or placebo subcutaneously twice weekly for 6 months. Subjects were evaluated for toxicity and disease progression. A significant decrease in mean virus load (VL) was observed for the GM-CSF treatment group at 6 months (-0.07 log(10) vs. -0.60 log(10); P=.02). More subjects achieved human immunodeficiency virus (HIV)-RNA levels <500 copies/mL at >/=2 evaluations (2% on placebo vs. 11% on GM-CSF; P=.04). Genotypic analysis of 46 subjects demonstrated a lower frequency of zidovudine-resistant mutations among those receiving GM-CSF (80% vs. 50%; P=.04). No difference was observed in the incidence of opportunistic infections (OIs) through 6 months or survival, despite a higher risk for OI among GM-CSF recipients. GM-CSF reduced VL and limited the evolution of zidovudine-resistant genotypes, potentially providing adjunctive therapy in HIV disease. (+info)HIV (human immunodeficiency virus) infection is a condition in which the body is infected with HIV, a type of retrovirus that attacks the body's immune system. HIV infection can lead to AIDS (acquired immunodeficiency syndrome), a condition in which the immune system is severely damaged and the body is unable to fight off infections and diseases.
There are several ways that HIV can be transmitted, including:
1. Sexual contact with an infected person
2. Sharing of needles or other drug paraphernalia with an infected person
3. Mother-to-child transmission during pregnancy, childbirth, or breastfeeding
4. Blood transfusions ( although this is rare in developed countries due to screening processes)
5. Organ transplantation (again, rare)
The symptoms of HIV infection can be mild at first and may not appear until several years after infection. These symptoms can include:
1. Fever
2. Fatigue
3. Swollen glands in the neck, armpits, and groin
4. Rash
5. Muscle aches and joint pain
6. Night sweats
7. Diarrhea
8. Weight loss
If left untreated, HIV infection can progress to AIDS, which is a life-threatening condition that can cause a wide range of symptoms, including:
1. Opportunistic infections (such as pneumocystis pneumonia)
2. Cancer (such as Kaposi's sarcoma)
3. Wasting syndrome
4. Neurological problems (such as dementia and seizures)
HIV infection is diagnosed through a combination of blood tests and physical examination. Treatment typically involves antiretroviral therapy (ART), which is a combination of medications that work together to suppress the virus and slow the progression of the disease.
Prevention methods for HIV infection include:
1. Safe sex practices, such as using condoms and dental dams
2. Avoiding sharing needles or other drug-injecting equipment
3. Avoiding mother-to-child transmission during pregnancy, childbirth, or breastfeeding
4. Post-exposure prophylaxis (PEP), which is a short-term treatment that can prevent infection after potential exposure to the virus
5. Pre-exposure prophylaxis (PrEP), which is a daily medication that can prevent infection in people who are at high risk of being exposed to the virus.
It's important to note that HIV infection is manageable with proper treatment and care, and that people living with HIV can lead long and healthy lives. However, it's important to be aware of the risks and take steps to prevent transmission.
The symptoms of AIDS can vary depending on the individual and the stage of the disease. Common symptoms include:
1. Fever
2. Fatigue
3. Swollen glands
4. Rash
5. Muscle aches and joint pain
6. Night sweats
7. Diarrhea
8. Weight loss
9. Memory loss and other neurological problems
10. Cancer and other opportunistic infections.
AIDS is diagnosed through blood tests that detect the presence of HIV antibodies or the virus itself. There is no cure for AIDS, but antiretroviral therapy (ART) can help manage the symptoms and slow the progression of the disease. Prevention methods include using condoms, pre-exposure prophylaxis (PrEP), and avoiding sharing needles or other injection equipment.
In summary, Acquired Immunodeficiency Syndrome (AIDS) is a severe and life-threatening condition caused by the Human Immunodeficiency Virus (HIV). It is characterized by a severely weakened immune system, which makes it difficult to fight off infections and diseases. While there is no cure for AIDS, antiretroviral therapy can help manage the symptoms and slow the progression of the disease. Prevention methods include using condoms, pre-exposure prophylaxis, and avoiding sharing needles or other injection equipment.
Examples of AROIs include:
1. Pneumocystis pneumonia (PCP): a type of pneumonia caused by the fungus Pneumocystis jirovecii.
2. Tuberculosis (TB): a bacterial infection that can affect the lungs, brain, or other organs.
3. Toxoplasmosis: an infection caused by the parasite Toxoplasma gondii that can affect the brain, eyes, and other organs.
4. Cryptococcosis: a fungal infection that can affect the lungs, brain, or skin.
5. Histoplasmosis: a fungal infection caused by Histoplasma capsulatum that can affect the lungs, skin, and other organs.
6. Aspergillosis: a fungal infection caused by Aspergillus species that can affect the lungs, sinuses, and other organs.
7. Candidiasis: a fungal infection caused by Candida species that can affect the mouth, throat, vagina, or skin.
8. Kaposi's sarcoma: a type of cancer that is caused by the human herpesvirus 8 (HHV-8) and can affect the skin and lymph nodes.
9. Wasting syndrome: a condition characterized by weight loss, fatigue, and diarrhea.
10. Opportunistic infections that can affect the gastrointestinal tract, such as cryptosporidiosis and isosporiasis.
AROIs are a major cause of morbidity and mortality in individuals with HIV/AIDS, and they can be prevented or treated with antimicrobial therapy, supportive care, and other interventions.
HALS typically involves the accumulation of fat in the face, neck, and torso, while the arms and legs become thin and wasted. This can lead to a characteristic "buffalo hump" appearance on the back of the neck and a "spare tire" around the waist. In addition to the cosmetic changes, HALS can also cause metabolic problems such as insulin resistance, high blood sugar, and high levels of lipids (fats) in the blood.
HIV-associated lipodystrophy syndrome is thought to be caused by a combination of factors, including genetics, hormonal imbalances, and side effects of certain HIV medications. Treatment for HALS typically involves a multidisciplinary approach, including lifestyle modifications such as diet and exercise, as well as medication therapy to manage metabolic abnormalities and reduce the risk of cardiovascular disease.
HIV-associated lipodystrophy syndrome is a significant health concern for individuals living with HIV, as it can increase the risk of other serious health problems such as heart disease and stroke. It is important for individuals infected with HIV to be aware of the risk of developing HALS and to work closely with their healthcare provider to manage this condition effectively.
HIV seropositivity is typically diagnosed through a blood test called an enzyme-linked immunosorbent assay (ELISA). This test detects the presence of antibodies against HIV in the blood by using specific proteins on the surface of the virus. If the test is positive, it means that the individual has been infected with HIV.
HIV seropositivity is an important diagnostic criterion for AIDS (Acquired Immune Deficiency Syndrome), which is a condition that develops when the immune system is severely damaged by HIV infection. AIDS is diagnosed based on a combination of symptoms and laboratory tests, including HIV seropositivity.
HIV seropositivity can be either primary (acute) or chronic. Primary HIV seropositivity occurs when an individual is first infected with HIV and their immune system produces antibodies against the virus. Chronic HIV seropositivity occurs when an individual has been living with HIV for a long time and their immune system has produced antibodies that remain in their bloodstream.
HIV seropositivity can have significant implications for an individual's health and quality of life, as well as their social and economic well-being. It is important for individuals who are HIV seropositive to receive appropriate medical care and support to manage their condition and prevent the transmission of HIV to others.
The condition is characterized by an exaggerated immune response, which can cause inflammation in various parts of the body, including the skin, eyes, lungs, and gastrointestinal tract. IRIS can manifest as a range of symptoms, such as fever, fatigue, pain, and swelling in the affected areas.
The exact cause of IRIS is not fully understood, but it is thought to be related to the restoration of immune function after being suppressed by HIV. When ART is initiated, the immune system begins to recover, and the body mounts an immune response against previously latent viral reservoirs. This can lead to inflammation and tissue damage in some individuals.
The diagnosis of IRIS is based on a combination of clinical findings, laboratory tests, and imaging studies. Treatment typically involves supportive care, such as antibiotics for bacterial infections, anti-inflammatory medications, and corticosteroids to reduce inflammation. In severe cases, hospitalization may be necessary.
Prevention strategies for IRIS include careful monitoring of patients on ART, early detection and treatment of opportunistic infections, and the use of corticosteroids to prevent or treat inflammation. It is important for healthcare providers to be aware of the risk of IRIS and to monitor patients closely, particularly during the early stages of ART. With appropriate management, most cases of IRIS resolve without long-term complications.
Viremia is a condition where the virus is present in the bloodstream, outside of infected cells or tissues. This can occur during the acute phase of an infection, when the virus is actively replicating and spreading throughout the body. Viremia can also be seen in chronic infections, where the virus may persist in the blood for longer periods of time.
In some cases, viremia can lead to the development of antibodies against the virus, which can help to neutralize it and prevent its spread. However, if the viremia is not controlled, it can cause serious complications, such as sepsis or organ damage.
Diagnosis of viremia typically involves laboratory tests, such as PCR (polymerase chain reaction) or ELISA (enzyme-linked immunosorbent assay), which can detect the presence of virus in the blood. Treatment of viremia depends on the underlying cause and may include antiviral medications, supportive care, and management of any related complications.
1. Group B streptococcus (GBS): This type of bacterial infection is the leading cause of infections in newborns. GBS can cause a range of complications, including pneumonia, meningitis, and sepsis.
2. Urinary tract infections (UTIs): These are common during pregnancy and can be caused by bacteria such as Escherichia coli (E. coli) or Staphylococcus saprophyticus. UTIs can lead to complications such as preterm labor and low birth weight.
3. HIV: Pregnant women who are infected with HIV can pass the virus to their baby during pregnancy, childbirth, or breastfeeding.
4. Toxoplasmosis: This is an infection caused by a parasite that can be transmitted to the fetus through the placenta. Toxoplasmosis can cause a range of complications, including birth defects and stillbirth.
5. Listeriosis: This is a rare infection caused by eating contaminated food, such as soft cheeses or hot dogs. Listeriosis can cause complications such as miscarriage, stillbirth, and premature labor.
6. Influenza: Pregnant women who contract the flu can be at higher risk for complications such as pneumonia and hospitalization.
7. Herpes simplex virus (HSV): This virus can cause complications such as preterm labor, low birth weight, and neonatal herpes.
8. Human parvovirus (HPV): This virus can cause complications such as preterm labor, low birth weight, and stillbirth.
9. Syphilis: This is a sexually transmitted infection that can be passed to the fetus during pregnancy, leading to complications such as stillbirth, premature birth, and congenital syphilis.
10. Chickenpox: Pregnant women who contract chickenpox can be at higher risk for complications such as preterm labor and low birth weight.
It's important to note that the risks associated with these infections are relatively low, and many pregnant women who contract them will have healthy pregnancies and healthy babies. However, it's still important to be aware of the risks and take steps to protect yourself and your baby.
Here are some ways to reduce your risk of infection during pregnancy:
1. Practice good hygiene: Wash your hands frequently, especially before preparing or eating food.
2. Avoid certain foods: Avoid consuming raw or undercooked meat, eggs, and dairy products, as well as unpasteurized juices and soft cheeses.
3. Get vaccinated: Get vaccinated against infections such as the flu and HPV.
4. Practice safe sex: Use condoms or other forms of barrier protection to prevent the spread of STIs.
5. Avoid close contact with people who are sick: If someone in your household is sick, try to avoid close contact with them if possible.
6. Keep your environment clean: Regularly clean and disinfect surfaces and objects that may be contaminated with germs.
7. Manage stress: High levels of stress can weaken your immune system and make you more susceptible to infection.
8. Get enough rest: Adequate sleep is essential for maintaining a healthy immune system.
9. Stay hydrated: Drink plenty of water throughout the day to help flush out harmful bacteria and viruses.
10. Consider taking prenatal vitamins: Prenatal vitamins can help support your immune system and overall health during pregnancy.
Remember, it's always better to be safe than sorry, so if you suspect that you may have been exposed to an infection or are experiencing symptoms of an infection during pregnancy, contact your healthcare provider right away. They can help determine the appropriate course of action and ensure that you and your baby stay healthy.
The exact cause of ADC is not fully understood, but it is believed to be related to the progression of HIV infection in the brain. As HIV replicates in the brain, it can damage brain cells and disrupt normal brain function.
ADC typically affects individuals who have advanced HIV infection and a low CD4 cell count (a measure of immune system health). It is more common in women than men and tends to occur at an older age.
There are several symptoms of ADC, including:
1. Cognitive impairment: difficulty with memory, concentration, and decision-making.
2. Changes in personality and behavior: depression, anxiety, and agitation.
3. Difficulty with speech and language: slurred speech, trouble finding the right words.
4. Coordination and balance problems: unsteadiness, tremors, and difficulty with movement.
5. Seizures: ADC can cause seizures, which can be a sign of a more severe form of the disorder.
There is no cure for ADC, but treatment can help manage its symptoms and slow its progression. Treatment typically involves a combination of antiretroviral therapy (ART) to suppress HIV replication, and medications to manage cognitive and behavioral symptoms. In addition, supportive care, such as physical therapy and occupational therapy, can help improve quality of life.
In conclusion, AIDS Dementia Complex (ADC) is a serious neurological disorder that affects individuals with advanced HIV infection. It is characterized by cognitive impairment, changes in personality and behavior, and difficulty with speech and movement. While there is no cure for ADC, treatment can help manage its symptoms and slow its progression.
Example of how the term 'Lymphoma, AIDS-Related' could be used in a medical context:
"The patient was diagnosed with AIDS-related lymphoma and was started on ART and chemotherapy to treat the cancer."
The infection occurs when the virus enters the retina and causes inflammation, which can lead to damage to the retinal cells and blood vessels. Symptoms of CMV retinitis may include blurred vision, sensitivity to light, and floaters. If left untreated, the infection can progress to scarring, retinal detachment, and blindness.
The diagnosis of CMV retinitis is based on a combination of clinical findings, including symptoms, physical examination, and imaging tests such as fluorescein angiography. Treatment typically involves antiviral medication to suppress the virus and prevent further damage to the retina. In severe cases, surgery may be necessary to remove inflamed tissue or repair damaged blood vessels.
Preventing CMV retinitis in high-risk individuals, such as those with HIV/AIDS or undergoing immunosuppressive therapy, is important to avoid vision loss. This includes regular monitoring for CMV infection and prompt treatment if an infection occurs. In addition, reducing the risk of HIV transmission through safe sex practices and needle exchange programs can also help prevent CMV retinitis in these individuals.
Overall, CMV retinitis is a serious complication of viral infection that can cause significant vision loss if left untreated. Early detection and prompt treatment are essential to prevent long-term visual impairment and improve outcomes for patients with this condition.
Coinfection can be caused by various factors, including:
1. Exposure to multiple pathogens: When an individual is exposed to multiple sources of infection, such as contaminated food or water, they may contract multiple pathogens simultaneously.
2. Weakened immune system: A compromised immune system can make it more difficult for the body to fight off infections, making it more susceptible to coinfection.
3. Increased opportunities for transmission: In some situations, such as in healthcare settings or during travel to areas with high infection rates, individuals may be more likely to come into contact with multiple pathogens.
Examples of common coinfections include:
1. HIV and tuberculosis (TB): TB is a common opportunistic infection that affects individuals with HIV/AIDS.
2. Malaria and bacterial infections: In areas where malaria is prevalent, individuals may also be at risk for bacterial infections such as pneumonia or diarrhea.
3. Influenza and Streptococcus pneumoniae: During flu season, individuals may be more susceptible to both influenza and bacterial infections such as pneumonia.
Coinfection can have significant consequences for an individual's health, including increased morbidity and mortality. Treatment of coinfections often requires a combination of antimicrobial therapies targeting each pathogen, as well as supportive care to manage symptoms and prevent complications.
Preventing coinfection is important for maintaining good health, especially in individuals with compromised immune systems. This can include:
1. Practicing good hygiene: Washing hands regularly and avoiding close contact with individuals who are sick can help reduce the risk of infection.
2. Getting vaccinated: Vaccines can protect against certain infections, such as influenza and pneumococcal disease.
3. Taking antimicrobial prophylaxis: In some cases, taking antibiotics or other antimicrobial drugs may be recommended to prevent infection in individuals who are at high risk of coinfection.
4. Managing underlying conditions: Effectively managing conditions such as HIV/AIDS, diabetes, and heart disease can help reduce the risk of infection and coinfection.
5. Avoiding risky behaviors: Avoiding risky behaviors such as sharing needles or engaging in unprotected sex can help reduce the risk of infection and coinfection.
Lipodystrophy can be caused by genetic mutations, hormonal imbalances, or certain medications. It can also be associated with other medical conditions such as metabolic disorders, endocrine problems, and neurological diseases.
The symptoms of lipodystrophy can vary depending on the type and severity of the condition. Common symptoms include:
1. Muscle wasting and weakness
2. Fat redistribution to certain areas of the body (such as the face, neck, and torso)
3. Metabolic problems such as insulin resistance and high blood sugar
4. Hormonal imbalances
5. Abnormal body shape and proportions
6. Poor wound healing
7. Easy bruising and bleeding
8. Increased risk of infections
9. Joint pain and stiffness
10. Mood changes such as depression, anxiety, and irritability
Treatment for lipodystrophy depends on the underlying cause of the condition. Medications, lifestyle modifications, and surgery may be used to manage symptoms and improve quality of life. In some cases, lipodystrophy can be a sign of an underlying medical condition that needs to be treated.
Lipodystrophy can have a significant impact on an individual's quality of life, affecting their physical appearance, self-esteem, and ability to perform daily activities. It is important to seek medical attention if symptoms persist or worsen over time. With proper diagnosis and treatment, individuals with lipodystrophy can improve their symptoms and overall health.
The exact cause of HIV Wasting Syndrome is not fully understood, but it is believed to be related to a combination of factors, including chronic inflammation, immune activation, and the direct effects of HIV on the body's metabolism. The syndrome typically affects individuals with advanced stages of HIV infection and can have a significant impact on their quality of life, functional status, and survival.
Symptoms of HIV Wasting Syndrome include:
1. Weight loss (more than 10% of body weight)
2. Muscle wasting and weakness
3. Fatigue
4. Decreased appetite
5. Diarrhea
6. Nausea and vomiting
7. Abdominal pain
8. Dehydration
9. Poor wound healing
10. Fever
Diagnosis of HIV Wasting Syndrome is based on a combination of clinical evaluation, laboratory tests, and imaging studies. Laboratory tests may include measurements of serum albumin, prealbumin, and transferrin, as well as assessment of inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6). Imaging studies, such as computed tomography (CT) or positron emission tomography (PET), may be used to evaluate body composition and tissue distribution.
Treatment of HIV Wasting Syndrome involves a combination of antiretroviral therapy (ART) and supportive care, including:
1. ART to suppress HIV replication and reduce inflammation
2. Nutritional support with high-calorie diets or supplements
3. Prophylaxis for opportunistic infections
4. Management of related complications such as diarrhea, nausea, and pain
5. Physical therapy to maintain muscle mass and strength.
In addition, HIV Wasting Syndrome is also associated with other comorbidities such as HIV-associated neuropathy, HIV-associated dementia, and HIV-related kidney disease, which can further complicate the management of wasting syndrome. Therefore, it is important to address these comorbidities simultaneously while managing HIV Wasting Syndrome.
Disease progression can be classified into several types based on the pattern of worsening:
1. Chronic progressive disease: In this type, the disease worsens steadily over time, with a gradual increase in symptoms and decline in function. Examples include rheumatoid arthritis, osteoarthritis, and Parkinson's disease.
2. Acute progressive disease: This type of disease worsens rapidly over a short period, often followed by periods of stability. Examples include sepsis, acute myocardial infarction (heart attack), and stroke.
3. Cyclical disease: In this type, the disease follows a cycle of worsening and improvement, with periodic exacerbations and remissions. Examples include multiple sclerosis, lupus, and rheumatoid arthritis.
4. Recurrent disease: This type is characterized by episodes of worsening followed by periods of recovery. Examples include migraine headaches, asthma, and appendicitis.
5. Catastrophic disease: In this type, the disease progresses rapidly and unpredictably, with a poor prognosis. Examples include cancer, AIDS, and organ failure.
Disease progression can be influenced by various factors, including:
1. Genetics: Some diseases are inherited and may have a predetermined course of progression.
2. Lifestyle: Factors such as smoking, lack of exercise, and poor diet can contribute to disease progression.
3. Environmental factors: Exposure to toxins, allergens, and other environmental stressors can influence disease progression.
4. Medical treatment: The effectiveness of medical treatment can impact disease progression, either by slowing or halting the disease process or by causing unintended side effects.
5. Co-morbidities: The presence of multiple diseases or conditions can interact and affect each other's progression.
Understanding the type and factors influencing disease progression is essential for developing effective treatment plans and improving patient outcomes.
There are two main forms of TB:
1. Active TB: This is the form of the disease where the bacteria are actively growing and causing symptoms such as coughing, fever, chest pain, and fatigue. Active TB can be contagious and can spread to others if not treated properly.
2. Latent TB: This is the form of the disease where the bacteria are present in the body but are not actively growing or causing symptoms. People with latent TB do not feel sick and are not contagious, but they can still become sick with active TB if their immune system is weakened.
TB is a major public health concern, especially in developing countries where access to healthcare may be limited. The disease is diagnosed through a combination of physical examination, medical imaging, and laboratory tests such as skin tests or blood tests. Treatment for TB typically involves a course of antibiotics, which can be effective in curing the disease if taken properly. However, drug-resistant forms of TB have emerged in some parts of the world, making treatment more challenging.
Preventive measures against TB include:
1. Vaccination with BCG (Bacille Calmette-Guérin) vaccine, which can provide some protection against severe forms of the disease but not against latent TB.
2. Avoiding close contact with people who have active TB, especially if they are coughing or sneezing.
3. Practicing good hygiene, such as covering one's mouth when coughing or sneezing and regularly washing hands.
4. Getting regular screenings for TB if you are in a high-risk group, such as healthcare workers or people with weakened immune systems.
5. Avoiding sharing personal items such as towels, utensils, or drinking glasses with people who have active TB.
Overall, while TB is a serious disease that can be challenging to treat and prevent, with the right measures in place, it is possible to reduce its impact on public health and improve outcomes for those affected by the disease.
Symptoms of AAN include:
1. Proteinuria (excess protein in the urine)
2. Hematuria (blood in the urine)
3. Reduced kidney function
4. Swelling in the legs and ankles
5. Fatigue
6. Weight loss
Causes and risk factors:
1. HIV infection
2. Chronic immune activation and inflammation
3. High blood pressure
4. Diabetes mellitus
5. Obesity
Diagnosis:
1. Urine test for protein and blood
2. Kidney function tests (estimated glomerular filtration rate)
3. Biopsy of the kidney to examine for inflammation and scarring
Treatment:
1. Antiretroviral therapy (ART) to control HIV infection
2. Blood pressure-lowering medications
3. Medications to control proteinuria (e.g., angiotensin-converting enzyme inhibitors or angiotensin receptor blockers)
4. Medications to reduce inflammation and slow progression of the disease (e.g., corticosteroids or immunosuppressive drugs)
5. Dialysis or kidney transplant for advanced ESRD
Prognosis:
The prognosis for AAN is generally poor, with a high risk of progression to ESRD and mortality. However, early detection and treatment can improve outcomes. It is essential for individuals living with HIV/AIDS to receive regular monitoring and screening for kidney disease to prevent or delay the progression of AAN.
A rare and aggressive type of cancer that affects the connective tissue cells of the body, including blood vessels, lymph nodes, and soft tissue. It is caused by the human herpesvirus 8 (HHV-8) and is more common in people with weakened immune systems, such as those with HIV/AIDS.
Symptoms:
* Painless lumps or lesions on the skin or mouth
* Fatigue
* Weight loss
* Night sweats
Diagnosis:
* Biopsy of affected tissue
* Imaging tests, such as CT scans or MRI
Treatment:
* Chemotherapy to shrink the tumors
* Radiation therapy to kill cancer cells
* Surgery to remove the affected tissue
Prognosis:
* Poor, especially in people with HIV/AIDS
Etymology:
* Named after the Hungarian-born Jewish doctor, Georg Kaposi, who first described the condition in 1872.
Example sentence: "The patient was diagnosed with lactic acidosis secondary to uncontrolled diabetes and was admitted to the intensive care unit for proper management."
IV drug use can cause a range of short-term and long-term health problems, including infections, abscesses, blood-borne illnesses such as HIV/AIDS and hepatitis, and overdose. In addition to physical health issues, IV substance abuse can also lead to mental health problems, financial and legal problems, and social isolation.
Treatment for IV substance abuse typically involves a combination of behavioral therapy and medication. Behavioral therapies such as cognitive-behavioral therapy (CBT) and contingency management can help individuals modify their drug-seeking behaviors and develop coping skills to maintain sobriety. Medications such as methadone, buprenorphine, and naltrexone can also be used to manage withdrawal symptoms and reduce cravings for drugs.
Prevention strategies for IV substance abuse include education and awareness campaigns, community-based outreach programs, and harm reduction services such as needle exchange programs. These strategies aim to reduce the initiation of IV drug use, particularly among young people and other vulnerable populations.
There are several types of hepatitis C, including genotype 1, which is the most common and accounts for approximately 70% of cases in the United States. Other genotypes include 2, 3, 4, 5, and 6. The symptoms of hepatitis C can range from mild to severe and may include fatigue, fever, loss of appetite, nausea, vomiting, joint pain, jaundice (yellowing of the skin and eyes), dark urine, pale stools, and itching all over the body. Some people with hepatitis C may not experience any symptoms at all.
Hepatitis C is diagnosed through a combination of blood tests that detect the presence of antibodies against HCV or the virus itself. Treatment typically involves a combination of medications, including interferon and ribavirin, which can cure the infection but may have side effects such as fatigue, nausea, and depression. In recent years, new drugs known as direct-acting antivirals (DAAs) have become available, which can cure the infection with fewer side effects and in a shorter period of time.
Prevention measures for hepatitis C include avoiding sharing needles or other drug paraphernalia, using condoms to prevent sexual transmission, and ensuring that any tattoos or piercings are performed with sterilized equipment. Vaccines are also available for people who are at high risk of contracting the virus, such as healthcare workers and individuals who engage in high-risk behaviors.
Overall, hepatitis C is a serious and common liver disease that can lead to significant health complications if left untreated. Fortunately, with advances in medical technology and treatment options, it is possible to manage and cure the virus with proper care and attention.
The parasite enters the body through the ingestion of contaminated food or water, and can cause a wide range of symptoms in people with healthy immune systems, including fever, headache, and swollen lymph nodes. However, those with compromised immune systems are more susceptible to severe symptoms, including seizures, confusion, and coma.
Diagnosis of cerebral toxoplasmosis is often made through a combination of physical examination, laboratory tests (such as PCR or IgG antibody detection), and imaging studies (such as CT or MRI scans). Treatment typically involves a combination of antiparasitic medications and supportive care to manage symptoms and prevent complications.
In severe cases, cerebral toxoplasmosis can lead to long-term neurological damage, including cognitive impairment and seizure disorders. Prevention of the disease is primarily focused on avoiding exposure to the parasite, which can be achieved through good hygiene practices (such as proper handling and cooking of meat) and avoiding contact with cat feces, which are a common source of infection.
Overall, cerebral toxoplasmosis is a serious opportunistic infection that can have significant neurological consequences in individuals with compromised immune systems. Prompt diagnosis and appropriate treatment are essential for preventing long-term complications and improving outcomes.
A type of meningitis caused by the fungus Cryptococcus neoformans, which can be found in soil and decaying organic matter. The fungus is more common in areas with warm climates and poor air quality. It can cause a variety of symptoms including fever, headache, stiff neck, nausea, vomiting, and mental confusion.
It is most commonly seen in people who have compromised immune systems (such as those with HIV/AIDS or taking immunosuppressive medications), and the elderly. It can be diagnosed by analyzing a sample of cerebrospinal fluid (CSF) for the presence of the fungus or its antigens, or through imaging studies such as CT or MRI scans. Treatment typically involves antifungal medications and supportive care to manage symptoms.
This type of pneumonia can cause severe respiratory symptoms, including cough, fever, chest pain, and difficulty breathing. It can also lead to respiratory failure and other complications if left untreated.
Pneumocystis pneumonia is diagnosed through a combination of physical examination, medical history, and diagnostic tests such as chest X-rays or CT scans, and blood tests. Treatment typically involves antifungal medications, and hospitalization may be necessary for severe cases.
Prevention measures include avoiding exposure to people with weakened immune systems, avoiding smoking, and maintaining good hygiene practices. Vaccines are also available for some populations at high risk of developing Pneumocystis pneumonia.
The term "leukoencephalopathy" refers to any disease or condition that affects the white matter of the brain, which is composed of nerve fibers covered in a fatty insulating substance called myelin. In LEPM, this degeneration occurs in multiple areas of the brain and spinal cord, leading to a multifocal pattern of damage.
The symptoms of LEPM usually become apparent in early childhood and may include:
* Vision loss or blurred vision
* Seizures
* Difficulty with movement and balance
* Cognitive decline
* Speech difficulties
As the disease progresses, patients may experience increasing disability and loss of motor function, leading to difficulties with walking, speaking, and performing everyday activities. The exact progression of LEPM is highly variable, and some individuals may experience more rapid decline than others.
The cause of LEPM is a genetic mutation in the PLP1 gene, which codes for a protein called proteolipid protein (PLP). This protein plays a critical role in the maintenance of myelin sheaths around nerve fibers, and mutations in the PLP1 gene lead to degeneration of these sheaths and the loss of axons.
There is currently no cure for LEPM, and treatment is focused on managing symptoms and slowing disease progression. This may include medications to control seizures, physical therapy to maintain muscle strength and flexibility, and vision aids to improve visual function. In some cases, bone marrow transplantation may be considered as a potential treatment option.
Overall, LEPM is a severe and debilitating disorder that can significantly impact the quality of life of affected individuals and their families. While there is currently no cure, ongoing research into the genetics and pathophysiology of this disease may lead to new treatment options in the future.
SAIDS was first identified in the 1980s in monkeys that were being used in research laboratories, and it has since been studied extensively as a model for HIV/AIDS research. Like HIV/AIDS, SAIDS is caused by the transmission of a virus from one animal to another through contact with infected bodily fluids, such as blood or semen.
The symptoms of SAIDS are similar to those of HIV/AIDS and include fever, fatigue, weight loss, and opportunistic infections. As the disease progresses, animals may also experience neurological symptoms, such as seizures and difficulty coordinating movements.
There is currently no cure for SAIDS, and treatment is focused on managing the symptoms and preventing complications. Research into the disease has led to a greater understanding of the immunopathogenesis of HIV/AIDS and has contributed to the development of new therapies for the disease.
SAIDS is important in medical research because it provides a valuable model for studying the immunopathogenesis of HIV/AIDS and for testing new therapies and vaccines. It also serves as a reminder of the importance of strict safety protocols when working with infectious agents, particularly in laboratory settings.
There are several types of dyslipidemias, including:
1. Hyperlipidemia: Elevated levels of lipids and lipoproteins in the blood, which can increase the risk of CVD.
2. Hypolipidemia: Low levels of lipids and lipoproteins in the blood, which can also increase the risk of CVD.
3. Mixed dyslipidemia: A combination of hyperlipidemia and hypolipidemia.
4. Familial dyslipidemia: An inherited condition that affects the levels of lipids and lipoproteins in the blood.
5. Acquired dyslipidemia: A condition caused by other factors, such as poor diet or medication side effects.
Dyslipidemias can be diagnosed through a variety of tests, including fasting blood sugar (FBS), lipid profile, and apolipoprotein testing. Treatment for dyslipidemias often involves lifestyle changes, such as dietary modifications and increased physical activity, as well as medications to lower cholesterol and triglycerides.
In conclusion, dyslipidemias are abnormalities in the levels or composition of lipids and lipoproteins in the blood that can increase the risk of CVD. They can be caused by a variety of factors and diagnosed through several tests. Treatment often involves lifestyle changes and medications to lower cholesterol and triglycerides.
The symptoms of MAC infection can vary depending on the severity of the infection and may include:
* Chronic cough
* Fatigue
* Weight loss
* Night sweats
* Chest pain
* Shortness of breath
MAC infections can affect various parts of the body, including the lungs, liver, spleen, and lymph nodes. The infection can be diagnosed through a variety of tests, such as chest X-rays, CT scans, blood tests, and lung biopsies.
Treatment for MAC infections typically involves a combination of antibiotics and supportive care to manage symptoms. The choice of antibiotics depends on the severity of the infection and the individual's medical history and health status. Surgical intervention may be necessary in some cases, such as when the infection is severe or has spread to other parts of the body.
Preventive measures for MAC infections include avoiding exposure to contaminated water or soil, maintaining good hand hygiene, and avoiding close contact with individuals who have compromised immune systems. Vaccines are not available for MAC infections, but ongoing research is exploring the development of vaccines to prevent these types of infections.
Overall, Mycobacterium avium-intracellulare infection is a serious and potentially life-threatening condition that requires prompt diagnosis and treatment by a healthcare professional. With appropriate management, individuals with MAC infections can experience significant improvement in their symptoms and quality of life.
The most common symptoms of anus neoplasms are bleeding from the anus, pain or discomfort in the anal area, itching or burning sensation in the anus, and a lump or swelling near the anus. These symptoms can be caused by various conditions, including hemorrhoids, anal fissures, and infections. However, if these symptoms persist or worsen over time, they may indicate the presence of an anus neoplasm.
The diagnosis of anus neoplasms is typically made through a combination of physical examination, endoscopy, and imaging tests such as CT scans or MRI scans. A biopsy may also be performed to confirm the presence of cancer cells.
Treatment for anus neoplasms depends on the stage and location of the cancer, as well as the patient's overall health. Surgery is often the primary treatment option, and may involve removing the tumor, a portion of the anus, or the entire anus. Radiation therapy and chemotherapy may also be used to shrink the tumor before surgery or to kill any remaining cancer cells after surgery.
Prevention of anus neoplasms is not always possible, but certain measures can reduce the risk of developing these types of cancers. These include maintaining a healthy diet and lifestyle, avoiding exposure to carcinogens such as tobacco smoke, and practicing safe sex to prevent human papillomavirus (HPV) infections, which can increase the risk of anus neoplasms. Early detection and treatment of precancerous changes in the anus, such as anal intraepithelial neoplasia, can also help prevent the development of invasive anus neoplasms.
Pulmonary tuberculosis typically affects the lungs but can also spread to other parts of the body, such as the brain, kidneys, or spine. The symptoms of pulmonary TB include coughing for more than three weeks, chest pain, fatigue, fever, night sweats, and weight loss.
Pulmonary tuberculosis is diagnosed by a combination of physical examination, medical history, laboratory tests, and radiologic imaging, such as chest X-rays or computed tomography (CT) scans. Treatment for pulmonary TB usually involves a combination of antibiotics and medications to manage symptoms.
Preventive measures for pulmonary tuberculosis include screening for latent TB infection in high-risk populations, such as healthcare workers and individuals with HIV/AIDS, and vaccination with the bacillus Calmette-Guérin (BCG) vaccine in countries where it is available.
Overall, pulmonary tuberculosis is a serious and potentially life-threatening disease that requires prompt diagnosis and treatment to prevent complications and death.
The definition of DILI has been revised several times over the years, but the most recent definition was published in 2013 by the International Consortium for DILI Research (ICDCR). According to this definition, DILI is defined as:
"A clinically significant alteration in liver function that is caused by a medication or other exogenous substance, and is not related to underlying liver disease. The alteration may be biochemical, morphological, or both, and may be acute or chronic."
The ICDCR definition includes several key features of DILI, including:
1. Clinically significant alteration in liver function: This means that the liver damage must be severe enough to cause symptoms or signs of liver dysfunction, such as jaundice, nausea, vomiting, or abdominal pain.
2. Caused by a medication or other exogenous substance: DILI is triggered by exposure to certain drugs or substances that are not related to underlying liver disease.
3. Not related to underlying liver disease: This means that the liver damage must not be caused by an underlying condition such as hepatitis B or C, alcoholic liver disease, or other genetic or metabolic disorders.
4. May be acute or chronic: DILI can occur as a sudden and severe injury (acute DILI) or as a slower and more insidious process (chronic DILI).
The ICDCR definition provides a standardized way of defining and diagnosing DILI, which is important for clinicians and researchers to better understand the cause of liver damage in patients who are taking medications. It also helps to identify the drugs or substances that are most likely to cause liver injury and to develop strategies for preventing or treating DILI.
Types of Substance-Related Disorders:
1. Alcohol Use Disorder (AUD): A chronic disease characterized by the excessive consumption of alcohol, leading to impaired control over drinking, social or personal problems, and increased risk of health issues.
2. Opioid Use Disorder (OUD): A chronic disease characterized by the excessive use of opioids, such as prescription painkillers or heroin, leading to withdrawal symptoms when the substance is not available.
3. Stimulant Use Disorder: A chronic disease characterized by the excessive use of stimulants, such as cocaine or amphetamines, leading to impaired control over use and increased risk of adverse effects.
4. Cannabis Use Disorder: A chronic disease characterized by the excessive use of cannabis, leading to impaired control over use and increased risk of adverse effects.
5. Hallucinogen Use Disorder: A chronic disease characterized by the excessive use of hallucinogens, such as LSD or psilocybin mushrooms, leading to impaired control over use and increased risk of adverse effects.
Causes and Risk Factors:
1. Genetics: Individuals with a family history of substance-related disorders are more likely to develop these conditions.
2. Mental health: Individuals with mental health conditions, such as depression or anxiety, may be more likely to use substances as a form of self-medication.
3. Environmental factors: Exposure to substances at an early age, peer pressure, and social environment can increase the risk of developing a substance-related disorder.
4. Brain chemistry: Substance use can alter brain chemistry, leading to dependence and addiction.
Symptoms:
1. Increased tolerance: The need to use more of the substance to achieve the desired effect.
2. Withdrawal: Experiencing symptoms such as anxiety, irritability, or nausea when the substance is not present.
3. Loss of control: Using more substance than intended or for longer than intended.
4. Neglecting responsibilities: Neglecting responsibilities at home, work, or school due to substance use.
5. Continued use despite negative consequences: Continuing to use the substance despite physical, emotional, or financial consequences.
Diagnosis:
1. Physical examination: A doctor may perform a physical examination to look for signs of substance use, such as track marks or changes in heart rate and blood pressure.
2. Laboratory tests: Blood or urine tests can confirm the presence of substances in the body.
3. Psychological evaluation: A mental health professional may conduct a psychological evaluation to assess symptoms of substance-related disorders and determine the presence of co-occurring conditions.
Treatment:
1. Detoxification: A medically-supervised detox program can help manage withdrawal symptoms and reduce the risk of complications.
2. Medications: Medications such as methadone or buprenorphine may be prescribed to manage withdrawal symptoms and reduce cravings.
3. Behavioral therapy: Cognitive-behavioral therapy (CBT) and contingency management are effective behavioral therapies for treating substance use disorders.
4. Support groups: Joining a support group such as Narcotics Anonymous can provide a sense of community and support for individuals in recovery.
5. Lifestyle changes: Making healthy lifestyle changes such as regular exercise, healthy eating, and getting enough sleep can help manage withdrawal symptoms and reduce cravings.
It's important to note that diagnosis and treatment of substance-related disorders is a complex process and should be individualized based on the specific needs and circumstances of each patient.
The infection is usually caused by an overgrowth of Candida, which is a normal flora in the mouth, but can become pathogenic under certain conditions. Risk factors for developing OC include taking antibiotics, wearing dentures, pregnancy, diabetes, and HIV/AIDS.
OC can be diagnosed by examining the mouth and throat with a mirror and torch, as well as through laboratory tests such as cultures or PCR. Treatment typically involves antifungal medication, good oral hygiene practices, and addressing any underlying conditions. In severe cases, hospitalization may be necessary.
Preventative measures include practicing good oral hygiene, avoiding smoking, and managing any underlying medical conditions. In addition, early diagnosis and treatment can help prevent the infection from spreading to other parts of the body, such as the bloodstream or heart.
1. Tooth decay (cavities): A bacterial infection that causes tooth enamel to break down, leading to holes in the teeth.
2. Periodontal disease: An infection of the gums and bone that support the teeth, caused by bacteria.
3. Gingivitis: Inflammation of the gums, usually caused by poor oral hygiene or smoking.
4. Oral thrush: A fungal infection of the mouth, typically affecting people with weakened immune systems.
5. Herpes simplex virus (HSV) infections: Viral infections that cause sores on the lips, tongue, or gums.
6. Cold sores: Caused by the herpes simplex virus, these are small, painful blisters that appear on the lips, nose, or mouth.
7. Canker sores: Small, shallow ulcers that develop on the inside of the mouth, tongue, lips, or gums.
8. Leukoplakia: A condition where thick, white patches form on the insides of the mouth, usually due to excessive tobacco use or other irritants.
9. Oral cancer: Cancer that develops in any part of the mouth, including the lips, tongue, gums, or throat.
10. Dry mouth (xerostomia): A condition where the mouth does not produce enough saliva, which can increase the risk of tooth decay and other problems.
These are just a few examples of mouth diseases. It's important to maintain good oral hygiene and visit a dentist regularly to help prevent these conditions and ensure early detection and treatment if they do occur.
There are several subtypes of NHL, including:
1. B-cell lymphomas (such as diffuse large B-cell lymphoma and follicular lymphoma)
2. T-cell lymphomas (such as peripheral T-cell lymphoma and mycosis fungoides)
3. Natural killer cell lymphomas (such as nasal NK/T-cell lymphoma)
4. Histiocyte-rich B-cell lymphoma
5. Primary mediastinal B-cell lymphoma
6. Mantle cell lymphoma
7. Waldenström macroglobulinemia
8. Lymphoplasmacytoid lymphoma
9. Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) related lymphoma
These subtypes can be further divided into other categories based on the specific characteristics of the cancer cells.
Symptoms of NHL can vary depending on the location and size of the tumor, but may include:
* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching
* Abdominal pain
* Swollen spleen
Treatment for NHL typically involves a combination of chemotherapy, radiation therapy, and in some cases, targeted therapy or immunotherapy. The specific treatment plan will depend on the subtype of NHL, the stage of the cancer, and other individual factors.
Overall, NHL is a complex and diverse group of cancers that require specialized care from a team of medical professionals, including hematologists, oncologists, radiation therapists, and other support staff. With advances in technology and treatment options, many people with NHL can achieve long-term remission or a cure.
The symptoms of hepatitis B can range from mild to severe and may include fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, pale stools, joint pain, and jaundice (yellowing of the skin and eyes). In some cases, hepatitis B can be asymptomatic, meaning that individuals may not experience any symptoms at all.
Hepatitis B is diagnosed through blood tests that detect the presence of HBV antigens or antibodies in the body. Treatment for acute hepatitis B typically involves rest, hydration, and medication to manage symptoms, while chronic hepatitis B may require ongoing therapy with antiviral drugs to suppress the virus and prevent liver damage.
Preventive measures for hepatitis B include vaccination, which is recommended for individuals at high risk of infection, such as healthcare workers, sexually active individuals, and those traveling to areas where HBV is common. In addition, safe sex practices, avoiding sharing of needles or other bodily fluids, and proper sterilization of medical equipment can help reduce the risk of transmission.
Overall, hepatitis B is a serious infection that can have long-term consequences for liver health, and it is important to take preventive measures and seek medical attention if symptoms persist or worsen over time.
Peripheral Nervous System Diseases can result from a variety of causes, including:
1. Trauma or injury
2. Infections such as Lyme disease or HIV
3. Autoimmune disorders such as Guillain-Barré syndrome
4. Genetic mutations
5. Tumors or cysts
6. Toxins or poisoning
7. Vitamin deficiencies
8. Chronic diseases such as diabetes or alcoholism
Some common Peripheral Nervous System Diseases include:
1. Neuropathy - damage to the nerves that can cause pain, numbness, and weakness in the affected areas.
2. Multiple Sclerosis (MS) - an autoimmune disease that affects the CNS and PNS, causing a range of symptoms including numbness, weakness, and vision problems.
3. Peripheral Neuropathy - damage to the nerves that can cause pain, numbness, and weakness in the affected areas.
4. Guillain-Barré syndrome - an autoimmune disorder that causes muscle weakness and paralysis.
5. Charcot-Marie-Tooth disease - a group of inherited disorders that affect the nerves in the feet and legs, leading to muscle weakness and wasting.
6. Friedreich's ataxia - an inherited disorder that affects the nerves in the spine and limbs, leading to coordination problems and muscle weakness.
7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - an autoimmune disorder that causes inflammation of the nerves, leading to pain, numbness, and weakness in the affected areas.
8. Amyotrophic Lateral Sclerosis (ALS) - a progressive neurological disease that affects the nerve cells responsible for controlling voluntary muscle movement, leading to muscle weakness, atrophy, and paralysis.
9. Spinal Muscular Atrophy - an inherited disorder that affects the nerve cells responsible for controlling voluntary muscle movement, leading to muscle weakness and wasting.
10. Muscular Dystrophy - a group of inherited disorders that affect the nerve cells responsible for controlling voluntary muscle movement, leading to muscle weakness and wasting.
It's important to note that this is not an exhaustive list and there may be other causes of muscle weakness. If you are experiencing persistent or severe muscle weakness, it is important to see a healthcare professional for proper evaluation and diagnosis.
The symptoms of cryptococcosis vary depending on the location and severity of the infection. In lung infections, patients may experience fever, cough, chest pain, and difficulty breathing. In CNS infections, patients may experience headaches, confusion, seizures, and loss of coordination. Skin infections can cause skin lesions, and eye infections can cause vision problems.
Cryptococcosis is diagnosed by culturing the fungus from body fluids or tissue samples. Treatment typically involves antifungal medications, such as amphotericin B or fluconazole, which may be given intravenously or orally, depending on the severity and location of the infection. In severe cases, surgery may be required to remove infected tissue or repair damaged organs.
Preventive measures for cryptococcosis include avoiding exposure to fungal spores, practicing good hygiene, and maintaining a healthy immune system. For individuals with HIV/AIDS, antiretroviral therapy can help reduce the risk of developing cryptococcosis.
Overall, while rare, cryptococcosis is a serious opportunistic infection that can affect individuals with compromised immune systems. Early diagnosis and prompt treatment are essential to prevent complications and improve outcomes.
The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the World Health Organization (WHO). In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.
In this article, we will explore the definition and impact of chronic diseases, as well as strategies for managing and living with them. We will also discuss the importance of early detection and prevention, as well as the role of healthcare providers in addressing the needs of individuals with chronic diseases.
What is a Chronic Disease?
A chronic disease is a condition that lasts for an extended period of time, often affecting daily life and activities. Unlike acute diseases, which have a specific beginning and end, chronic diseases are long-term and persistent. Examples of chronic diseases include:
1. Diabetes
2. Heart disease
3. Arthritis
4. Asthma
5. Cancer
6. Chronic obstructive pulmonary disease (COPD)
7. Chronic kidney disease (CKD)
8. Hypertension
9. Osteoporosis
10. Stroke
Impact of Chronic Diseases
The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the WHO. In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.
Chronic diseases can also have a significant impact on an individual's quality of life, limiting their ability to participate in activities they enjoy and affecting their relationships with family and friends. Moreover, the financial burden of chronic diseases can lead to poverty and reduce economic productivity, thus having a broader societal impact.
Addressing Chronic Diseases
Given the significant burden of chronic diseases, it is essential that we address them effectively. This requires a multi-faceted approach that includes:
1. Lifestyle modifications: Encouraging healthy behaviors such as regular physical activity, a balanced diet, and smoking cessation can help prevent and manage chronic diseases.
2. Early detection and diagnosis: Identifying risk factors and detecting diseases early can help prevent or delay their progression.
3. Medication management: Effective medication management is crucial for controlling symptoms and slowing disease progression.
4. Multi-disciplinary care: Collaboration between healthcare providers, patients, and families is essential for managing chronic diseases.
5. Health promotion and disease prevention: Educating individuals about the risks of chronic diseases and promoting healthy behaviors can help prevent their onset.
6. Addressing social determinants of health: Social determinants such as poverty, education, and employment can have a significant impact on health outcomes. Addressing these factors is essential for reducing health disparities and improving overall health.
7. Investing in healthcare infrastructure: Investing in healthcare infrastructure, technology, and research is necessary to improve disease detection, diagnosis, and treatment.
8. Encouraging policy change: Policy changes can help create supportive environments for healthy behaviors and reduce the burden of chronic diseases.
9. Increasing public awareness: Raising public awareness about the risks and consequences of chronic diseases can help individuals make informed decisions about their health.
10. Providing support for caregivers: Chronic diseases can have a significant impact on family members and caregivers, so providing them with support is essential for improving overall health outcomes.
Conclusion
Chronic diseases are a major public health burden that affect millions of people worldwide. Addressing these diseases requires a multi-faceted approach that includes lifestyle changes, addressing social determinants of health, investing in healthcare infrastructure, encouraging policy change, increasing public awareness, and providing support for caregivers. By taking a comprehensive approach to chronic disease prevention and management, we can improve the health and well-being of individuals and communities worldwide.
1. Autoimmune diseases: These occur when the immune system mistakenly attacks healthy cells and tissues in the body. Examples include rheumatoid arthritis, lupus, multiple sclerosis, and type 1 diabetes.
2. Allergies: An allergic reaction occurs when the immune system overreacts to a harmless substance, such as pollen, dust mites, or certain foods. Symptoms can range from mild hives to life-threatening anaphylaxis.
3. Immunodeficiency disorders: These are conditions that impair the immune system's ability to fight infections. Examples include HIV/AIDS and primary immunodeficiency diseases.
4. Infectious diseases: Certain infections, such as tuberculosis or bacterial meningitis, can cause immune system dysfunction.
5. Cancer: Some types of cancer, such as lymphoma, affect the immune system's ability to fight disease.
6. Immune thrombocytopenic purpura (ITP): This is a rare autoimmune disorder that causes the immune system to attack and destroy platelets, leading to bleeding and bruising.
7. Guillain-Barré syndrome: This is a rare autoimmune disorder that occurs when the immune system attacks the nerves, leading to muscle weakness and paralysis.
8. Chronic fatigue syndrome (CFS): This is a condition characterized by persistent fatigue, muscle pain, and joint pain, which is thought to be related to an immune system imbalance.
9. Fibromyalgia: This is a chronic condition characterized by widespread muscle pain, fatigue, and sleep disturbances, which may be linked to immune system dysfunction.
10. Autoimmune hepatitis: This is a condition in which the immune system attacks the liver, leading to inflammation and damage to the liver cells.
It's important to note that a weakened immune system can increase the risk of infections and other health problems, so it's important to work with your healthcare provider to identify any underlying causes and develop an appropriate treatment plan.
Some common flaviviridae infections include:
1. Dengue fever: A viral infection that is common in tropical and subtropical regions, particularly in urban areas with poor sanitation and hygiene. It is transmitted by the bite of infected Aedes mosquitoes.
2. Yellow fever: A viral hemorrhagic disease that is found in tropical Africa and South America. It is transmitted by the bite of infected Haemagogus or Sabethes mosquitoes.
3. Zika virus disease: A viral infection that is primarily transmitted through the bite of infected Aedes mosquitoes. It can cause fever, rash, joint pain, and other symptoms.
4. West Nile virus disease: A viral infection that is primarily transmitted through the bite of infected Culex mosquitoes. It can cause fever, headache, muscle weakness, and other symptoms.
5. Japanese encephalitis: A viral infection that is found in parts of Asia and is transmitted by the bite of infected Culex or Japenese house mosquitoes. It can cause fever, headache, and other symptoms.
Flaviviridae infections can be diagnosed through a variety of tests, including blood tests and PCR (polymerase chain reaction) assays. Treatment is typically focused on relieving symptoms and supporting the body's immune system, and may include antiviral medications in some cases. Prevention includes measures to avoid mosquito bites, such as using insect repellents, wearing protective clothing, and eliminating standing water around homes and communities. Vaccines are also available for some flaviviridae infections, such as yellow fever and Japanese encephalitis.
The symptoms of chronic hepatitis C may be mild or absent, but some people experience fatigue, joint pain, muscle aches, nausea, loss of appetite, and jaundice (yellowing of the skin and eyes).
Chronic hepatitis C is usually diagnosed through blood tests that detect the presence of antibodies against HCV or the virus itself. Imaging tests such as ultrasound and liver biopsy may also be performed to assess the extent of liver damage.
Treatment for chronic hepatitis C typically involves a combination of medications, including interferon and ribavirin, which can help clear the virus from the body. In severe cases, a liver transplant may be necessary. Prevention of the spread of HCV includes avoiding sharing of needles or other sharp objects, practicing safe sex, and getting tested for the virus before donating blood or organs.
See also: Hepatitis C; Liver; Virus
These diseases can cause a wide range of symptoms such as fatigue, weight changes, and poor wound healing. Treatment options vary depending on the specific condition but may include lifestyle changes, medications, or surgery.
A persistent infection with the hepatitis B virus (HBV) that can lead to liver cirrhosis and hepatocellular carcinoma. HBV is a bloodborne pathogen and can be spread through contact with infected blood, sexual contact, or vertical transmission from mother to child during childbirth.
Chronic hepatitis B is characterized by the presence of HBsAg in the blood for more than 6 months, indicating that the virus is still present in the liver. The disease can be asymptomatic or symptomatic, with symptoms such as fatigue, malaise, loss of appetite, nausea, vomiting, joint pain, and jaundice.
Chronic hepatitis B is diagnosed through serological tests such as HBsAg, anti-HBc, and HBV DNA. Treatment options include interferon alpha and nucleos(t)ide analogues, which can slow the progression of the disease but do not cure it.
Prevention strategies for chronic hepatitis B include vaccination with hepatitis B vaccine, which is effective in preventing acute and chronic HBV infection, as well as avoidance of risky behaviors such as unprotected sex and sharing of needles.
CMV infections are more common in people with weakened immune systems, such as those with HIV/AIDS, cancer, or taking immunosuppressive drugs after an organ transplant. In these individuals, CMV can cause severe and life-threatening complications, such as pneumonia, retinitis (inflammation of the retina), and gastrointestinal disease.
In healthy individuals, CMV infections are usually mild and may not cause any symptoms at all. However, in some cases, CMV can cause a mononucleosis-like illness with fever, fatigue, and swollen lymph nodes.
CMV infections are diagnosed through a combination of physical examination, blood tests, and imaging studies such as CT scans or MRI. Treatment is generally not necessary for mild cases, but may include antiviral medications for more severe infections. Prevention strategies include avoiding close contact with individuals who have CMV, practicing good hygiene, and considering immunoprophylaxis (prevention of infection through the use of immune globulin) for high-risk individuals.
Overall, while CMV infections can be serious and life-threatening, they are relatively rare in healthy individuals and can often be treated effectively with supportive care and antiviral medications.
The condition can be caused by a variety of factors, including excessive alcohol consumption, viral hepatitis, non-alcoholic fatty liver disease, and certain medications. It can also be a complication of other diseases such as hemochromatosis and Wilson's disease.
The symptoms of liver cirrhosis can vary depending on the severity of the disease, but may include fatigue, loss of appetite, nausea, abdominal swelling, and pain in the upper right side of the abdomen. As the disease progresses, it can lead to complications such as esophageal varices, ascites, and liver failure, which can be life-threatening.
There is no cure for liver cirrhosis, but treatment options are available to manage the symptoms and slow the progression of the disease. These may include medications to control swelling and pain, dietary changes, and in severe cases, liver transplantation. In some cases, a liver transplant may be necessary if the disease has caused significant damage and there is no other option to save the patient's life.
In conclusion, liver cirrhosis is a serious and potentially life-threatening condition that can cause significant damage to the liver and lead to complications such as liver failure. It is important for individuals to be aware of the risk factors and symptoms of the disease in order to seek medical attention if they suspect they may have liver cirrhosis. With proper treatment and management, it is possible to slow the progression of the disease and improve the patient's quality of life.
There are many different types of anemia, each with its own set of causes and symptoms. Some common types of anemia include:
1. Iron-deficiency anemia: This is the most common type of anemia and is caused by a lack of iron in the diet or a problem with the body's ability to absorb iron. Iron is essential for making hemoglobin.
2. Vitamin deficiency anemia: This type of anemia is caused by a lack of vitamins, such as vitamin B12 or folate, that are necessary for red blood cell production.
3. Anemia of chronic disease: This type of anemia is seen in people with chronic diseases, such as kidney disease, rheumatoid arthritis, and cancer.
4. Sickle cell anemia: This is a genetic disorder that affects the structure of hemoglobin and causes red blood cells to be shaped like crescents or sickles.
5. Thalassemia: This is a genetic disorder that affects the production of hemoglobin and can cause anemia, fatigue, and other health problems.
The symptoms of anemia can vary depending on the type and severity of the condition. Common symptoms include fatigue, weakness, pale skin, shortness of breath, and dizziness or lightheadedness. Anemia can be diagnosed with a blood test that measures the number and size of red blood cells, as well as the levels of hemoglobin and other nutrients.
Treatment for anemia depends on the underlying cause of the condition. In some cases, dietary changes or supplements may be sufficient to treat anemia. For example, people with iron-deficiency anemia may need to increase their intake of iron-rich foods or take iron supplements. In other cases, medical treatment may be necessary to address underlying conditions such as kidney disease or cancer.
Preventing anemia is important for maintaining good health and preventing complications. To prevent anemia, it is important to eat a balanced diet that includes plenty of iron-rich foods, vitamin C-rich foods, and other essential nutrients. It is also important to avoid certain substances that can interfere with the absorption of nutrients, such as alcohol and caffeine. Additionally, it is important to manage any underlying medical conditions and seek medical attention if symptoms of anemia persist or worsen over time.
In conclusion, anemia is a common blood disorder that can have significant health implications if left untreated. It is important to be aware of the different types of anemia, their causes, and symptoms in order to seek medical attention if necessary. With proper diagnosis and treatment, many cases of anemia can be successfully managed and prevented.
1. Protein-energy malnutrition (PEM): This type of malnutrition is caused by a lack of protein and energy in the diet. It is common in developing countries and can lead to weight loss, weakness, and stunted growth in children.
2. Iron deficiency anemia: This type of malnutrition is caused by a lack of iron in the diet, which is necessary for the production of hemoglobin in red blood cells. Symptoms include fatigue, weakness, and shortness of breath.
3. Vitamin and mineral deficiencies: Malnutrition can also be caused by a lack of essential vitamins and minerals such as vitamin A, vitamin D, calcium, and iodine. Symptoms vary depending on the specific deficiency but can include skin problems, impaired immune function, and poor wound healing.
4. Obesity: This type of malnutrition is caused by consuming too many calories and not enough nutrients. It can lead to a range of health problems including diabetes, high blood pressure, and heart disease.
Signs and symptoms of malnutrition can include:
* Weight loss or weight gain
* Fatigue or weakness
* Poor wound healing
* Hair loss
* Skin problems
* Increased infections
* Poor appetite or overeating
* Digestive problems such as diarrhea or constipation
* Impaired immune function
Treatment for malnutrition depends on the underlying cause and may include:
* Dietary changes: Eating a balanced diet that includes a variety of nutrient-rich foods can help to correct nutrient deficiencies.
* Nutritional supplements: In some cases, nutritional supplements such as vitamins or minerals may be recommended to help address specific deficiencies.
* Medical treatment: Certain medical conditions that contribute to malnutrition, such as digestive disorders or infections, may require treatment with medication or other interventions.
Prevention is key, and there are several steps you can take to help prevent malnutrition:
* Eat a balanced diet that includes a variety of nutrient-rich foods.
* Avoid restrictive diets or fad diets that limit specific food groups.
* Stay hydrated by drinking plenty of water.
* Avoid excessive alcohol consumption, which can interfere with nutrient absorption and lead to malnutrition.
* Maintain a healthy weight through a combination of a balanced diet and regular exercise.
It is important to note that malnutrition can be subtle and may not always be easily recognizable. If you suspect you or someone you know may be experiencing malnutrition, it is important to seek medical attention to receive an accurate diagnosis and appropriate treatment.
Types of Cognition Disorders: There are several types of cognitive disorders that affect different aspects of cognitive functioning. Some common types include:
1. Attention Deficit Hyperactivity Disorder (ADHD): Characterized by symptoms of inattention, hyperactivity, and impulsivity.
2. Traumatic Brain Injury (TBI): Caused by a blow or jolt to the head that disrupts brain function, resulting in cognitive, emotional, and behavioral changes.
3. Alzheimer's Disease: A progressive neurodegenerative disorder characterized by memory loss, confusion, and difficulty with communication.
4. Stroke: A condition where blood flow to the brain is interrupted, leading to cognitive impairment and other symptoms.
5. Parkinson's Disease: A neurodegenerative disorder that affects movement, balance, and cognition.
6. Huntington's Disease: An inherited disorder that causes progressive damage to the brain, leading to cognitive decline and other symptoms.
7. Frontotemporal Dementia (FTD): A group of neurodegenerative disorders characterized by changes in personality, behavior, and language.
8. Post-Traumatic Stress Disorder (PTSD): A condition that develops after a traumatic event, characterized by symptoms such as anxiety, avoidance, and hypervigilance.
9. Mild Cognitive Impairment (MCI): A condition characterized by memory loss and other cognitive symptoms that are more severe than normal age-related changes but not severe enough to interfere with daily life.
Causes and Risk Factors: The causes of cognition disorders can vary depending on the specific disorder, but some common risk factors include:
1. Genetics: Many cognitive disorders have a genetic component, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.
2. Age: As people age, their risk of developing cognitive disorders increases, such as Alzheimer's disease, vascular dementia, and frontotemporal dementia.
3. Lifestyle factors: Factors such as physical inactivity, smoking, and poor diet can increase the risk of cognitive decline and dementia.
4. Traumatic brain injury: A severe blow to the head or a traumatic brain injury can increase the risk of developing cognitive disorders, such as chronic traumatic encephalopathy (CTE).
5. Infections: Certain infections, such as meningitis and encephalitis, can cause cognitive disorders if they damage the brain tissue.
6. Stroke or other cardiovascular conditions: A stroke or other cardiovascular conditions can cause cognitive disorders by damaging the blood vessels in the brain.
7. Chronic substance abuse: Long-term use of drugs or alcohol can damage the brain and increase the risk of cognitive disorders, such as dementia.
8. Sleep disorders: Sleep disorders, such as sleep apnea, can increase the risk of cognitive disorders, such as dementia.
9. Depression and anxiety: Mental health conditions, such as depression and anxiety, can increase the risk of cognitive decline and dementia.
10. Environmental factors: Exposure to certain environmental toxins, such as pesticides and heavy metals, has been linked to an increased risk of cognitive disorders.
It's important to note that not everyone with these risk factors will develop a cognitive disorder, and some people without any known risk factors can still develop a cognitive disorder. If you have concerns about your cognitive health, it's important to speak with a healthcare professional for proper evaluation and diagnosis.
1. Coronary artery disease: The narrowing or blockage of the coronary arteries, which supply blood to the heart.
2. Heart failure: A condition in which the heart is unable to pump enough blood to meet the body's needs.
3. Arrhythmias: Abnormal heart rhythms that can be too fast, too slow, or irregular.
4. Heart valve disease: Problems with the heart valves that control blood flow through the heart.
5. Heart muscle disease (cardiomyopathy): Disease of the heart muscle that can lead to heart failure.
6. Congenital heart disease: Defects in the heart's structure and function that are present at birth.
7. Peripheral artery disease: The narrowing or blockage of blood vessels that supply oxygen and nutrients to the arms, legs, and other organs.
8. Deep vein thrombosis (DVT): A blood clot that forms in a deep vein, usually in the leg.
9. Pulmonary embolism: A blockage in one of the arteries in the lungs, which can be caused by a blood clot or other debris.
10. Stroke: A condition in which there is a lack of oxygen to the brain due to a blockage or rupture of blood vessels.
Recurrence can also refer to the re-emergence of symptoms in a previously treated condition, such as a chronic pain condition that returns after a period of remission.
In medical research, recurrence is often studied to understand the underlying causes of disease progression and to develop new treatments and interventions to prevent or delay its return.
Vaccinia immune globulin
Deborah Persaud
Anand Reddi
Discovery and development of non-nucleoside reverse-transcriptase inhibitors
Ramani Durvasula
Ritonavir
Lipoatrophy
Economic epidemiology
Progressive multifocal leukoencephalopathy
HIV associated cardiomyopathy
Zidovudine
Hepatitis
AIDS-related lymphoma
Treatment as prevention
Immune reconstitution inflammatory syndrome
Cachexia
Virus latency
Viral load monitoring for HIV
Valerie E. Stone
Isosporiasis
Histoplasma duboisii
Howard E. Gendelman
Douglas Jabs
Harriet Mayanja-Kizza
Didanosine
Supervised injection site
Andrew Kambugu
Cryptosporidiosis
Mycobacterium avium-intracellulare infection
Julio Montaner
Indinavir
2022 monkeypox outbreak
Decoy cells
Antimicrobial
Haplogroup L2 (mtDNA)
Robert Yarchoan
Enzyme inhibitor
PharmAccess Foundation
Timeline of LGBT history in the United Kingdom
Douglas Richman
Pharmaceutical industry
APOBEC3G
History of medicine
WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents
Valproate
Division of Acquired Immunodeficiency Syndrome
Oral manifestations of systemic disease
Leronlimab
Janice E. Clements
Jennifer Thorne
Chronic condition
Metabolic syndrome
Men who have sex with men
Central African Republic
HIV vaccine development
Hairy leukoplakia
Infection
SARS-CoV-2 Omicron variant
NIH Guide: HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) CARDIOVASCULAR TOXICITIES
Browsing by Subject "Antiretroviral Therapy, Highly Active"
Adherence assessment to highly active antiretroviral therapy - PubMed
Liver failure in a child receiving highly active antiretroviral therapy and voriconazole - PubMed
NIH VideoCast - Hepatitis C and Its Treatment - AIDS: Opportunistic Infections in the Era of Highly Active Antiretroviral...
WHO EMRO | Parametric modelling of survival following HIV and AIDS in the era of highly active antiretroviral therapy: data...
Alopecia Universalis Associated with Vitiligo in an 18-year-old HIV-positive Patient: Highly Active Anti-retroviral Therapy as...
Sleep quality and immune changes in HIV positive people in the first six months of starting highly active antiretroviral...
Subjects: Antiretroviral Therapy, Highly Active - Digital Collections - National Library of Medicine Search Results
Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era
Guidelines for Using Antiretroviral Agents Among
HIV-Infected Adults and Adolescents
Highly Active Antiretroviral Therapies Are Effectiv... | preLekára.sk
Publication: Highly active antiretroviral therapy decreases mortality and morbidity in patients …
Assessment of liver and renal functions in human immunodeficiency virus-infected persons on highly active antiretroviral...
The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV...
Risks of cardio-vascular diseases among highly active antiretroviral therapy (HAART) treated HIV seropositive volunteers at a...
Results of search for 'su:{Antiretroviral therapy, Highly active}'
›
WHO HQ Library catalog
Preventing Cryptococcosis-Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy
Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. | CIRA
Prolonged Treatment Interruption after Immunologic Response to Highly Active Antiretroviral Therapy<...
HIV-1 dementia: A metabolic encephalopathy abrogated by highly active antiretroviral therapy (HAART) - HSC
Diarrhea Rates With Lopinavir-Ritonavir or Nelfinavir
Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy ...
HIV Medicines | HIV Cure | HIV Treatment | MedlinePlus
Predictors of Adherence to Highly Active Antiretroviral Therapy among HIV Patients attending Selected Comprehensive Care ...
Browsing WHA54 by Subject
The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women<...
Virologic and Immunologic Responses in Patients on Highly Active Antiretroviral Active Therapy in Vhembe District, South Africa...
JCI -
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic
HAART15
- With the advent of highly active antiretroviral therapy (HAART), the reduction in overall mortality and morbidity in HIV patients has been accompanied by the emergence of liver disease as a leading cause of death. (nih.gov)
- Many dermatological conditions have been described in HIV-infected patients, either in the context of an uncontrolled HIV infection or in the situation of highly active anti-retroviral therapy (HAART). (medicaljournals.se)
- BACKGROUND: Mortality and morbidity related to AIDS have decreased among HIV-infected patients taking highly active anti-retroviral therapy (HAART), but previous studies may have been confounded by other changes in treatment. (nih.gov)
- RESULTS: At baseline, patients had a median CD4(+) lymphocyte count of 0.015 x 10(9) cell/L, median plasma HIV RNA level of 4.8 log(10) copies/mL, and median hemoglobin concentration of 73 g/L. Use of HAART increased from 1% of active patients in January 1996 to 79% of active patients in January 1999. (nih.gov)
- Indian data on potential hepatorenal toxic effects of highly active antiretroviral therapy ( HAART ) in HIV / AIDS -affected persons is lacking. (bvsalud.org)
- The major HAART regimens included zidovudine + lamivudine + nevirapine in 175 (43.8%), tenofovir + lamivudine + efavirenz in 174 (43.5%) and zidovudine + lamivudine + efavirenz in 20 (5%) individuals and were associated with grade-1 hepatic dysfunction in 57 (14.3%) individuals, with men aged between 31 and 45 years on antiretroviral therapy for >5 years being mainly affected. (bvsalud.org)
- Highly active antiretroviral therapy (HAART) prolongs short-term survival in patients with HIV/AIDS. (yale.edu)
- This observational cohort study was conducted among HIV-infected, antiretroviral therapy (ART) naive children in Phnom Penh, Cambodia, to evaluate the feasibility and efficacy of highly active antiretroviral therapy (HAART) delivered using a modified directly observed therapy (MDOT) protocol. (umassmed.edu)
- [ 1 ] Many patients receiving highly active anti-retroviral therapy (HAART) experience an increase in CD4 + cell counts or stabilization of declining CD4 + cell counts. (medscape.com)
- Background: In the early highly active antiretroviral therapy (HAART) era, kidney dysfunction was strongly associated with death among HIV-infected individuals. (elsevierpure.com)
- The introduction of highly active antiretroviral therapy (HAART) has led to a significant reduction in AIDS-related morbidity and mortality. (cmaj.ca)
- 1 , 2 , 3 Unfortunately, up to 25% of patients discontinue their initial HAART regimen because of treatment failure (inability to suppress HIV viral replication to below the current limit of detection, 50 copies/mL), toxic effects or noncompliance within the first 8 months of therapy. (cmaj.ca)
- In this article we review the adverse effects of HAART therapy, with specific attention to the metabolic abnormalities associated with HIV treatment, including dyslipidemias, diabetes mellitus, insulin resistance, and the lipodystrophy syndrome and lactic acidosis associated with NRTI mitochondrial toxicity. (cmaj.ca)
- Several uncommon but more serious adverse effects associated with antiretroviral therapy, including AZT-associated anemia, d4T-associated peripheral neuropathy, PI-associated retinoid toxicity (exemplified by pruritus and ingrown toenails) and NNRTI-associated hypersensitivity reactions, are treated according to accepted therapy for these conditions in patients not receiving HAART. (cmaj.ca)
- This combination approach is called highly active antiretroviral therapy, or HAART. (nih.gov)
Regimens6
- Antiretroviral drug regimens are strongly suspected as one factor responsible for adult and pediatric cardiac dysfunction. (nih.gov)
- Our results suggest that the ability to suppress high viral MOI is a feature of effective ART regimens and this parameter should be considered when designing novel antiviral therapies. (prelekara.sk)
- The availability of an increasing number of antiretroviral agents and the rapid evolution of new information has introduced substantial complexity into treatment regimens for persons infected with human immunodeficiency virus (HIV). (cdc.gov)
- Antiretroviral regimens are complex, have serious side effects, pose difficulty with adherence, and carry serious potential consequences from the development of viral resistance because of nonadherence to the drug regimen or suboptimal levels of antiretroviral agents. (cdc.gov)
- [ 2 , 5 ] With antiretroviral regimens containing protease inhibitors, the frequency of diarrhea due to infectious agents has decreased, likely due to CD4 + cell count improvements. (medscape.com)
- Common but mild adverse effects occurring early in most antiretroviral regimens include gastrointestinal effects such as bloating, nausea and diarrhea, which may be transient or may persist throughout therapy. (cmaj.ca)
Adherence7
- Antiretroviral therapy and adherence, men has sex with men, mental health, substance abuse, stigma, and Sub-Saharan Africa were the central topics regarding the depression-related research in HIV/AIDS. (frontiersin.org)
- Non-adherence to Antiretroviral Therapy is a major challenge to AIDS care, and the risks associated with it are extensive. (who.int)
- To assess factors associated with non-adherence among AIDS patients receiving Antiretroviral Therapy at Yirgalem Hospital, Southern Ethiopia. (who.int)
- Provision of Antiretroviral Therapy (ART) in adherence to more than 95% of doses (13, 14). (who.int)
- Poor adherence to antiretroviral therapy negatively affects the suppression of viral replication. (biomedcentral.com)
- Adherence of antiretroviral therapy in this study was comparable to other studies conducted in developing countries. (biomedcentral.com)
- Caregiver's knowledge about antiretroviral therapy, no current use of substances, close proximity to health facilities, and letting child's know his/her HIV status improves adherence to antiretroviral therapy. (biomedcentral.com)
AIDS4
- AIDS : opportunistic infections in the era of highly active antiretroviral therapy / Henry Masur. (nih.gov)
- Several covariates-age, sex, combined HIV exposure category, CD4 cell counts, antiretroviral treatment and AIDS-defining illnesses-were included in the parametric model to predict factors associated with future mortality. (who.int)
- Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. (yale.edu)
- and genetic , metabolic , and other factors that influence how HIV infection may progress to the active diseases of AIDS. (nih.gov)
Cohort study1
- Assessment of liver and renal functions in human immunodeficiency virus-infected persons on highly active antiretroviral therapy: A mixed cohort study. (bvsalud.org)
Infection6
- HIV screening revealed a chronic HIV infection with a CD4 T cells count as low as 9 cells/mm 3 and a highly increased HIV viraemia, at 280,000 copies/ml. (medicaljournals.se)
- The high local multiplicity of infection (MOI) observed at cell-cell contact sites may lower the efficacy of antiretroviral therapies (ART). (prelekara.sk)
- 1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. (prelekara.sk)
- Report of the NIH Panel To Define Principles of Therapy of HIV Infection and Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. (cdc.gov)
- Determine how antiretroviral therapy (ART) affects other medical conditions, including the timing of treatments after HIV infection. (nih.gov)
- For children who have had HIV-1 infection since birth, the combination drug therapies now used to treat HIV appear to protect against the heart damage seen before combination therapies were available, according to researchers in a National Institutes of Health network study. (nih.gov)
Morbidity and morta1
- Protease inhibitor-based combination antiretroviral therapy has reduced morbidity and mortality dramatically among persons infected with human immunodeficiency virus (HIV). (medscape.com)
Hepatotoxicity2
- Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. (nih.gov)
- Preexisting anemia appears an important risk factor for highly active antiretroviral therapy -induced hepatotoxicity (OR 1.90, Cl 95% CI 1.02-3.57, P = 0.04). (bvsalud.org)
Protease inhibitors1
- We demonstrate that, while some nucleoside-analog reverse transcriptase inhibitors (NRTI) are less effective against HIV-1 cell-to-cell transmission, most non-nucleoside-analog reverse transcriptase inhibitors (NNRTI), entry inhibitors and protease inhibitors remain highly effective. (prelekara.sk)
Regimen2
- The study reflects the low frequency of regimen based highly active antiretroviral therapy -associated hepatic or nephrotoxicity despite prolonged use, especially in the absence of other risk factors . (bvsalud.org)
- To determine and compare rates of diarrhea in patients receiving an antiretroviral regimen containing lopinavir-ritonavir versus nelfinavir and in patients who received these drugs sequentially. (medscape.com)
Mortality1
- Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. (nih.gov)
Antiviral1
- My research interests include the study of vaccine-preventable diseases and viral respiratory diseases in young children and immunocompromised hosts, including transplant recipients, as well as the evaluation of antiviral therapy for the prevention and treatment of viral diseases. (seattlechildrens.org)
Zidovudine2
- Furthermore, basic research studies have focused on the NRTI, zidovudine and not combination therapies. (nih.gov)
- Therapy with zidovudine, lamivudine, and indinavir was initiated and within 2 weeks a marked improvement in mental function was seen. (unthsc.edu)
Interruption1
- Duration of treatment interruption (TI) was investigated in 105 human immunodeficiency virus-infected patients whose antiretroviral therapy was interrupted with the intention to resume therapy on the basis of clinical or laboratory indicators. (johnshopkins.edu)
Initiation1
- Patients who met current United States Department of Health and Human Services criteria for starting therapy at the time of therapy initiation were 3 times more likely to resume therapy than were those who did not. (johnshopkins.edu)
NRTIs2
- Thus, the contribution of NRTIs and/or combination therapies to the cellular mechanisms involved in these pathologies have not been well defined. (nih.gov)
- Moreover, poor NRTIs become highly effective when applied in combinations explaining the effectiveness of ART in clinical settings. (prelekara.sk)
Treatment4
- A public health approach to antiretroviral treatment : overcoming constraints / Ian Grubb, Jos Perriëns, Bernhard Schwartländer. (who.int)
- Of the 10 antiretroviral-naïve patients who received lopinavir-ritonavir, none needed treatment for diarrhea, whereas 78 (36%) of 217 antiretroviral-naïve patients who received nelfinavir required treatment for diarrhea. (medscape.com)
- The treatment of HIV with medicines is called antiretroviral therapy (ART). (medlineplus.gov)
- Therapy for FSGS includes nonspecific measures (eg, nutrition) and symptomatic treatment. (medscape.com)
Efficacy1
- Here we test the efficacy of commonly used antiretroviral inhibitors against cell-to-cell and cell-free HIV-1 transmission. (prelekara.sk)
Prevention1
- However, several behavioral and structural strategies have made a difference - male circumcision provides substantial protection from sexually transmitted diseases, including HIV-1, and the application of antiretroviral agents for prevention holds great promise. (jci.org)
Acquired immunode1
- We describe a 10-year-old child with vertically transmitted acquired immunodeficiency syndrome who was receiving antiretroviral combination therapy and died of liver failure after beginning voriconazole therapy. (nih.gov)
Adverse6
- All antiretroviral drugs can have both short-term and long-term adverse events. (cmaj.ca)
- A better understanding of the adverse effects of antiretroviral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV-positive patients. (cmaj.ca)
- While development of new antiretroviral agents continues, efforts to maximize the effectiveness of currently available treatments include attempts to better understand and manage adverse effects. (cmaj.ca)
- Each antiretroviral medication is associated with its own specific adverse effects or may cause problems only in particular circumstances. (cmaj.ca)
- Antiretroviral therapy can have a wide range of adverse effects on the human body ( Fig. 1 ). (cmaj.ca)
- Fig. 1: Adverse effects of antiretroviral therapy. (cmaj.ca)
Patient2
- Alopecia Universalis Associated with Vitiligo in an 18-year-old HIV-positive Patient: Highly Active Anti-retroviral Therapy as First Choice Therapy? (medicaljournals.se)
- The patient was subsequently lost to follow-up and developed Grave's disease in January 2010, 1 month after re-introduction of anti-retroviral therapy. (medicaljournals.se)
Exposure1
- o Studies to evaluate the mechanisms and effects of in utero exposure to antiretroviral drugs on the heart, including but not exclusively limited to cardiac development, dysfunction, and/or mitochondrial abnormalities. (nih.gov)
Metabolic1
- However, new clinical complications have emerged as a result of the therapy, including peripheral and coronary arterial diseases, and metabolic disturbances seen typically in diabetes. (nih.gov)
Significant2
- Highly active antiretroviral therapy -associated nephrotoxicity was not a significant problem. (bvsalud.org)
- Finally, when we quantified immune cell TSPO surface expression in antiretroviral therapy-treated HIV+ donors, a chronic inflammatory disease, we found significant increases in the frequency of TSPO surface localization, which could be pharmacologically suppressed with ∆9 -tetrahydrocannabinol. (nih.gov)
Medication1
- The study included a directly observed therapy phase (months 1-3) and a medication self-administration phase (months 4-18). (umassmed.edu)
Drug3
- In the early 1990s, children with HIV were not treated with anti-HIV therapy or were treated with only one drug. (nih.gov)
- However, doctors knew little about whether combination anti-HIV drug therapies could affect the heart. (nih.gov)
- The criteria included that participants had relapsed due to non-compliance with drug therapy. (up.ac.za)
Liver1
- Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy]. (nih.gov)
Agents2
- Failure of therapy at 4--6 months might be ascribed to nonadherence, inadequate potency of drugs or suboptimal levels of antiretroviral agents, viral resistance, and other factors that are poorly understood. (cdc.gov)
- Data collected included antidiarrheal agents dispensed, baseline viral load and CD4 + cell counts, demographic variables, and previous therapy. (medscape.com)
Introduction of highly active1
- Alopecia universalis (a) prior to, and (b) after, the introduction of highly active anti-retroviral therapy. (medicaljournals.se)
Hospital1
- Brazil showed the cumulative incidence of non- receiving Antiretroviral Therapy at Yirgalem Hospital. (who.int)
Hypertension1
- The prevalence of HIV-associated pulmonary arterial hypertension (PAH) has not been evaluated since introduction of combined, highly active antiretroviral treatments. (nih.gov)
Cell2
- Highly Active Antiretroviral Therapies Are Effective against HIV-1 Cell-to-Cell Transmission. (prelekara.sk)
- Patients in the lopinavir-ritonavir group were more likely to have received highly active antiretroviral therapy and azithromycin than patients receiving nelfinavir, and they had lower baseline CD4 + cell counts (p≤0.01 for each comparison). (medscape.com)
Care1
- Health care providers should educate caregivers about antiretroviral therapy and encourage HIV positive status disclosure to the child. (biomedcentral.com)
Renal2
- In addition, uremia and conditions associated with renal replacement therapy are fraught with numerous and, often, relatively unique cutaneous disorders. (medscape.com)
- Review of the 2019 report reveals that diabetes mellitus remains the most common cause of ESRD, responsible for approximately 42% of all patients on renal replacement therapy. (medscape.com)
Subject1
- Is the Subject Area "Highly-active antiretroviral therapy" applicable to this article? (plos.org)
Combination therapy1
- 1997) Decay characteristics of HIV-1-infected compartments during combination therapy. (prelekara.sk)
Children2
- A total of 464 children who were taking Antiretroviral Therapy (ART) in the hospitals were included. (biomedcentral.com)
- A total of 78.6% of the caregivers reported that their children were adherent to antiretroviral therapy in the month prior to the interview. (biomedcentral.com)
Results1
- Our results have implications for this TI strategy: there may be a subset of patients who can safely discontinue therapy for prolonged periods of time. (johnshopkins.edu)